Consultation on the protection and enforcement of IP rights in third countries
Position Paper
25 Nov 2020
Healthcare, Intellectual property

The American Chamber of Commerce to the European Union (AmCham EU) welcomes the European Commission’s ongoing efforts to advance strong and balanced intellectual property rights (IPR) globally. Together with the EU Counterfeit and Piracy Watch List, the biannual report on the protection and enforcement of IPR in third countries is an important tool in assessing the scale and scope of the challenges being faced, and in determining where to focus the EU’s efforts. US businesses invested in and committed to Europe often rely on the appropriate legal frameworks in third countries regarding IPR. These US companies invest and innovate in a range of critical sectors, including life sciences, digital, audiovisual and consumer goods. Such innovations bring benefits to citizens, patients and consumers, as well as the broader economy – not just in Europe or the US, but across the globe.

We call upon the European Commission to strengthen its focus on securing sustainable improvements to the IP environment in third counties. The Commission’s work with third countries should include a focus on strengthening rules and technical capabilities of authorities, clear and measurable objectives in improving prosecution of bad actors, reduction of exported infringements and ease of resolving civil disputes between competitors. The mechanisms to support this may include further dialogue and engagement of third country governments and other stakeholders, technical programmes (eg, IP Key), negotiating ambitious IP provisions in EU Free Trade Agreements (FTAs), and critically the Commission’s new trade enforcement strategy, which strengthens the implementation and enforcement of EU trade policy, including for IP. In addition, we also encourage reinforcing existing collaborations, including with the US. AmCham EU stands ready to work with the European Commission in achieving those goals and in sharing insight on other countries and the IPR challenges faced by our companies globally.

Related items

News
20 May 2026

Healthcare, competitiveness, innovation and simplification

Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation. 

The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment. 

The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains. 

Healthcare
Simplification
Read more
Read more about Healthcare, competitiveness, innovation and simplification
Position Paper
19 May 2026

Strengthening EU competitiveness through an adaptive MDR/IVDR framework

Healthcare
Read more
Read more about Strengthening EU competitiveness through an adaptive MDR/IVDR framework
Position Paper
19 May 2026

A global approach to strengthening Europe’s biotechnology ecosystem

Healthcare
Read more
Read more about A global approach to strengthening Europe’s biotechnology ecosystem